COPD News

BOSTON — Having a COPD exacerbation hospitalization in combination with COVID-19 vs. no COVID-19 significantly raised the odds for mortality and invasive ventilation, according to a poster presented at the CHEST Annual Meeting.

BOSTON — Women with COPD who live in rural areas have poorer Environmental Justice Index scores indicating disparities than those who live in urban areas, according to a study presented at the CHEST Annual Meeting.

BOSTON — Receiving dupilumab for 52 weeks led to health-related quality of life improvement in adults with COPD and type 2 inflammation, according to a pooled analysis of BOREAS and NOTUS presented at the CHEST Annual Meeting.

BOSTON — The odds for mortality, ventilation and septic shock among adults hospitalized with COPD went down if they also had GERD, according to data presented at the CHEST Annual Meeting.

BOSTON — Older adults hospitalized for an acute COPD exacerbation with vs. without metabolically healthy obesity were more likely to experience respiratory and cardiac complications, according to data presented at the CHEST Annual Meeting.

Using continuous temperature monitoring data from patients with COPD, an AI was able to predict exacerbations, according to a poster presented at the European Respiratory Society International Congress.

Tomorrow, Oct. 2, several lung and respiratory organizations will come together to celebrate World Oxygen Day and patients using oxygen therapy.

Patients with COPD on budesonide/glycopyrrolate/formoterol fumarate within 30 days of an exacerbation had fewer future exacerbations and severe cardiopulmonary events, according to a study poster.

The FDA has granted approval to dupilumab for treating adults with poorly controlled COPD with type 2 inflammation, according to a manufacturer-issued press release.

Among adults with COPD and bronchitis, receiving 600 mg of tozorakimab every 4 weeks may lead to FEV1 improvement, according to a poster presented at the European Respiratory Society International Congress.